DelfaGLP-1 Atlas

Lead sponsor

Stanford University

8 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

8

Trials led

4

Active

722

Total enrollment

5

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
2
Not applicable
1

Trials by status

Not yet recruiting
1
Recruiting
3
Completed
4

Trials led

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted PreventionBMI ≥23Ph 4Not yet recruiting200
Stanford Pediatric Healthy Weight Index—not applicableRecruiting120
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or TirzepatideBMI 19-24.9Ph 4Recruiting104
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.BMI 27-37Ph 3Completed69
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/ObesityBMI 27-39.9Ph 2Recruiting66
Exenatide and Weight Loss for Diabetes PreventionBMI 27-37Ph 1Completed66
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and BloodBMI 25-42Ph 1Completed56
LGTBMI 27-37Ph 1Completed41